Cortagen vs Chonluten
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Cortagen is a synthetic tetrapeptide (Ala-Glu-Asp-Pro) developed at the St. Petersburg Institute of Bioregulation as a cardioprotective and vascular bioregulator. It stimulates repair of cardiac and vascular tissue, with demonstrated benefits for coronary artery disease, atherosclerosis, and cardiac aging.
- Chonluten is a tripeptide bioregulator (Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific to the bronchi and lungs. While related to Bronchogen (a tetrapeptide), Chonluten is a shorter tripeptide sequence. It supports bronchial mucosal cell function, promotes respiratory epithelial regeneration, and is used in protocols for COPD, chronic bronchitis, and pulmonary anti-aging.
- Half-Life
- Short peptide half-life; gene regulatory effects persist beyond peptide clearance
- Short (minutes for the peptide); sustained gene-regulatory effects
- Admin Route
- SubQ, IM, Oral
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 10 mg SC or IM daily
- 10 mg per day
- Frequency
- Once daily
- Daily for 10–30 days
- Key Benefits
- Cardioprotective — protects cardiac tissue from ischemic damage
- Promotes cardiac regeneration and repair
- Improves vascular endothelium function
- Reduces atherosclerosis progression
- Anti-aging effect on heart muscle cells
- Improves cardiac output and exercise capacity
- Reduces oxidative stress in cardiovascular tissue
- May reduce arrhythmia frequency
- Supports bronchial mucosal regeneration and repair
- May improve mucociliary clearance in chronic respiratory conditions
- Anti-inflammatory effects on bronchial epithelium
- Pulmonary anti-aging and tissue preservation
- Supports lung function in COPD and chronic bronchitis
- Well tolerated in combination with other Khavinson bioregulators
- Short tripeptide with efficient cellular penetration
- Side Effects
- Excellent safety profile
- Mild injection site reactions
- Rare: transient hypotension
- Rare: mild arrhythmia at initiation in cardiac patients
- Generally well tolerated
- Mild injection site reactions possible
- No significant adverse pulmonary events reported
- Stacks With
- —
- —